Product Information
Sermorelin
Sermorelin is a synthetic peptide made of 29 amino acids. [1]
Ingredient & Research Information [1]
- Growth hormone signaling
- Injection and troche forms
- Limited adult clinical evidence
[1] Source · Additional source: Historical Geref approvals do not approve current compounded injections, troches or adult longevity uses, and injection research does not establish troche outcomes.
Is Sermorelin Peptide Therapy the Better Solution To Growth Hormone Insufficiency?
Updated November 4, 2026 · Product information
Sermorelin is a synthetic 29-amino-acid peptide that prompts the pituitary gland to release growth hormone (GH), and you can evaluate whether it fits your health goals by reviewing comprehensive blood work with a licensed physician. At Opt Health, we analyze baseline endocrine biomarkers before our physicians consider prescribing any peptide formulation. Published clinical trials show that sermorelin influences nocturnal hormone release, but the data does not demonstrate broad biological age reversal or guaranteed changes in body composition. (Source).
Structure and Pituitary Signaling of Sermorelin Peptide
Sermorelin corresponds to the amino-terminal fragment of native human growth hormone-releasing hormone (GHRH) and acts directly on the anterior pituitary gland. This mechanism was examined in human trials such as PMID 9005976, where administration of the 1 to 29 peptide sequence triggered measurable increases in circulating GH.
When patients evaluate secretagogue pathways with a physician, they often compare distinct signaling profiles. You can review how this mechanism compares with alternative options by examining sermorelin vs ipamorelin or reading sermorelin vs CJC-1295. (Source).
Endocrine and Functional Outcomes in Older Men
Human research on standard GHRH 1-29 shows measurable increases in nocturnal hormone release alongside clear boundaries in physical composition. In a six-week clinical investigation conducted by Vittone et al. (1997), researchers evaluated eleven healthy ambulatory men between 64 and 76 years of age who presented with low baseline insulin-like growth factor-I (IGF-I) levels. Participants received nightly subcutaneous injections of GHRH 1-29 to assess changes in hormone secretion, muscle performance, and body composition.
Endocrine monitoring in the trial demonstrated targeted nocturnal hormone elevations. Mean nocturnal GH release rose significantly (P < 0.02), along with the area under the hormone peak (P < 0.006) and peak amplitude (P < 0.05). Morning serum IGF-I showed no statistically significant change across the six weeks, as reported in PMID 9005976.
Functional assessments revealed improvements across three tested physical metrics. Participants achieved statistically significant gains in two out of six tested strength exercises, specifically the upright row (P < 0.02) and the shoulder press (P < 0.04). Muscular endurance during an abdominal crunch evaluation also improved (P < 0.03), though muscle histology remained unchanged in the Vittone et al. (1997) dataset.
Despite specific functional gains, objective physical composition did not change during the study. Dual-energy x-ray absorptiometry (DEXA) scans showed no shifts in lean muscle tissue or fat mass. Body weight, body mass index, waist-to-hip ratio, fasting lipids, and oral glucose tolerance test (OGTT) responses remained unaltered throughout the evaluation documented in PMID 9005976.
Evidence Boundaries in Modified Analog Research
Clinical findings from altered peptide analogs show distinct hormonal actions that cannot serve as evidence for standard sermorelin. In a five-month single-blind study published by Khorram et al. (1997), researchers evaluated nineteen older adults (ten women and nine men aged 55 to 71 years) who received nightly injections of a modified analog known as [Nle27]GHRH-(1-29)-NH2 for sixteen weeks following a four-week placebo phase. This is a modified analog rather than standard sermorelin.
The modified analog elicited sex-specific endocrine and metabolic responses over the treatment period. Nightly administration stimulated an acute release of GH within ten minutes that lasted for two hours, yielding an increase in twelve-hour integrated nocturnal GH levels in both women (P < 0.01) and men (P < 0.05). Serum IGF-I rose within two weeks, but concentrations returned toward baseline by week sixteen in both sexes, as detailed in PMID 9141536.
Physical changes in the modified analog trial diverged sharply between male and female participants. Male subjects achieved a statistically significant increase in lean body mass (P < 0.05) measured by DEXA, whereas female subjects showed no change in lean mass. Men also demonstrated an improvement in insulin sensitivity assessed by intravenous glucose tolerance testing (P < 0.05), which was not observed in women, though both sexes showed increased skin thickness (P < 0.05) in PMID 9141536.
Subjective outcome measures in the Khorram et al. (1997) trial showed clear limits. Male participants recorded higher scores for general well-being (P < 0.05) and libido (P < 0.01), but female participants showed no change in these categories. Sleep quality evaluated through questionnaires was unaffected across both sexes, and the only observed adverse effect was transient hyperlipidemia that resolved by the end of the trial.
Regulatory History and Compounding Standards
FDA has not approved compounded sermorelin for adult anti-aging therapies, athletic recovery, or wellness enhancement. Historical regulatory records show that an injectable sermorelin product under the trade name Geref previously held approval for pediatric indications and clinical diagnostic protocols. The regulatory background is documented in the FDA Federal Register Determination, which confirms that Geref was approved for treating childhood idiopathic growth hormone deficiency accompanied by growth failure. (Source).
The Federal Register notice records that the manufacturer discontinued Geref voluntarily. FDA formally determined that the product was not withdrawn from sale for reasons of safety or effectiveness. That historical finding does not constitute regulatory approval for modern compounded formulations, which do not undergo FDA pre-market safety or efficacy evaluations, as explained in the FDA Compounding Q&A.
Injection and Troche Formulations
The Opt Health store lists injectable sermorelin and a sermorelin troche. In our online pharmacy catalog, sermorelin troches dissolve in the mouth. (Official store listing). (Source).
Clinical Candidacy and Physician Discussion Questions
Sourced clinical data from PMID 9005976 demonstrates that standard GHRH 1-29 did not alter body weight, fat mass, or overall muscle composition in healthy older men.
Before meeting with a physician to discuss sermorelin, prepare concrete questions to guide your consultation: (Source).
- Do my baseline IGF-I and endocrine biomarkers suggest decreased growth hormone secretion?
- What specific physical or functional endpoints will we monitor to assess my response to therapy?
- How do the documented outcomes of GHRH 1-29 compare with the goals I have for my physical health?
- What are the clinical differences between sublingual troches and subcutaneous injections for my daily routine?
- Which follow-up measures will we review to assess response and side effects?
The Opt Take on Sermorelin Peptide
At Opt Health, we evaluate sermorelin through rigorous diagnostic measurement rather than speculative wellness trends. We do not prescribe peptides based on subjective symptoms alone. Your medical evaluation begins with our comprehensive blood panel examining 55+ biomarkers across hormone levels, cardiovascular risk factors, and metabolic indicators, which you can explore on how it works.
Following your diagnostic test, you sit down for a one-on-one video consultation with an Opt Health physician to review your lab findings and medical history. Prescriptions, peptides, and supplements can ship from our pharmacy to your home. We anchor every medical plan to our six foundational health pillars: sleep, stress, hormones, exercise, inflammation, and nutrition. (Source).
Follow-up blood panels and physician consultations inform plan adjustments. Follow-up blood panels and physician consultations occur on a regular schedule determined by your membership tier, while our clinical team remains accessible through our app seven days a week. Get started: Begin with Opt Health, where a physician reads your labs, builds your plan, and adjusts it over the loop. (Source).
Frequently Asked Questions
What is the biological function of sermorelin peptide?
Sermorelin is a synthetic peptide containing the first 29 amino acids of native human growth hormone-releasing hormone. It binds to receptors on the anterior pituitary gland to stimulate the natural secretion of endogenous growth hormone, as documented in clinical investigations such as PMID 9005976.
Has sermorelin received FDA approval for anti-aging therapy?
The FDA has not approved sermorelin for anti-aging, body recomposition, or longevity enhancement. Historical approval was granted to the branded drug Geref for childhood growth hormone deficiency and diagnostic testing before it was voluntarily discontinued, as detailed in the FDA Federal Register Notice. Compounded sermorelin troches and injections are prepared under valid prescriptions and are not evaluated or approved by FDA for safety or efficacy, as explained in published FDA Compounding Q&A.
Did clinical trials find that sermorelin improves sleep quality?
The cited modified-analog study found no improvement in questionnaire-based sleep quality. In a sixteen-week trial of a modified GHRH analog published under PMID 9141536, subjective sleep quality scores remained unchanged between placebo and active treatment phases in both men and women.
What changes in body composition did human trials observe?
The human study of standard GHRH 1-29 indexed in PMID 9005976 reported no changes in body weight, body mass index, or lean and fat mass measured by dual-energy x-ray absorptiometry scans. In a separate trial evaluating a modified norleucine analog in PMID 9141536, men experienced an increase in lean body mass, but women did not, and neither sex showed changes in overall body weight.
How should compounded sermorelin be stored?
Follow the specific handling and storage guidelines provided on the prescription label by the dispensing pharmacy.
Explore our tiered Opt Health Memberships to review diagnostic testing and physician consultations.
References
- Vittone J, et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism. 1997;46(1):89-96. Available from: https://pubmed.ncbi.nlm.nih.gov/9005976/
- Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. The Journal of Clinical Endocrinology & Metabolism. 1997;82(5):1472-1479. Available from: https://pubmed.ncbi.nlm.nih.gov/9141536/
- FDA. Determination That Geref (Sermorelin Acetate) Injection and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness. Federal Register. 2013;78(44):14561-14562. Available from: https://public-inspection.federalregister.gov/2013-04827.pdf
- FDA. Compounding and the FDA: Questions and Answers. Available from: https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
- FDA. FDA Reminds Compounders to Use Ingredients Suitable for Sterile Compounding. October 30, 2024. Available from: https://www.fda.gov/drugs/human-drug-compounding/fda-reminds-compounders-use-ingredients-suitable-sterile-compounding
Medical Disclaimer: The information provided in this article is for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. Compounded medications are prepared pursuant to a valid prescription from a licensed healthcare practitioner and are not evaluated or approved by the FDA for safety or efficacy. Always seek the advice of your physician or other qualified healthcare provider regarding any medical condition or treatment plan.
This article is part of our guide to peptides. See how peptide therapy is prescribed and monitored at Opt Health.
Start Today
Your health, your terms. Discover how personalized care can transform not just the way you feel, but how you live.
